Latest news with #MSDPharmaceuticals
Time of India
a day ago
- Health
- Time of India
Why protecting your child from certain preventable cancers should be a top priority
*IMAGE FOR REPRESENTATION PURPOSE ONLY As a parent, you plan various aspects of your child's future. But it is easy to overlook a key investment during their teen years: their health. This is an important time in their life when the foundations for future well-being can be laid which can make a huge difference. You were diligent with the childhood immunisation shots, and that protection continues. But did you know that there is prevention available including vaccination for certain types of cancers like cervical cancer, anal cancer? These are caused by HPV or the human papilloma virus – a commonly transmitted virus that often functions silently and may not show any symptoms. While most HPV infections clear on their own, but if it persists, it can lead to certain types of cancers and other complications. Like any good investment, in health as well, acting early can yield better results. Taking preventive steps for your child during adolescence with HPV vaccination , between 9 and 14 years old, can yield better protection against certain HPV related cancers and diseases compared to when vaccinated later. At this age, their bodies build a more lasting immunity, providing strong protection before they are at risk of certain HPV related cancers and diseases. And this is not just for girls. HPV poses a risk of various cancers in both men and women. Protecting both boys and girls helps reduce some of these HPV related risks. We often see investment in health as 'optional' step because it's not an immediate risk, but a small investment today is nothing compared to the cost of a future illness. Prevention and protection are one of the important tools we have today against certain HPV related cancers. If you have questions, you are not alone. The best first step is a simple chat with your child's paediatrician, who can answer your questions and guide you. Don't wait, the earlier this protection begins, the better it may be. It is a simple step that can help protect your child against risk of certain HPV related cancers and diseases. Issued in public interest by MSD Pharmaceuticals for awareness purposes. References: 1. Questions and Answers about Human Papillomavirus (HPV). WHO (regional office for Europe) 2020, accessed on 2nd July 2025 2. HPV FAQ & Questions | Help You Understand Diagnosis & Treatment. Accessed on 2nd July 2025 IN-GSL-01402 25-Jul 2025 24-Jul 2027 Disclaimer : The views and opinions expressed in the story are independent professional judgments of the experts, and TIL does not take any responsibility for the accuracy of their views. This article has been produced on behalf of MSD Pharmaceuticals by Times Internet's Spotlight team.
The Hindu
18-06-2025
- Business
- The Hindu
Abbott to distribute MSD's diabetes drug in India
Abbott and MSD Pharmaceuticals have entered into a distribution agreement for MSD's oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version in India. Leveraging its broad footprint in the country Abbott will distribute the portfolio. The products are marketed under brand names Januvia, Janumet and Janumet XR, the companies said in a joint statement. Sitagliptin is a Dipeptidyl Peptidase IV Inhibitors used for treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity, they said. 'Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health,' V-P of Abbott in India Ambati Venu said. MSD India Region Managing Director Rehan A. Khan said, 'Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'
&w=3840&q=100)
Business Standard
18-06-2025
- Health
- Business Standard
Abbott, MSD join hands to distribute key diabetic drug across India
Two multinational drug makers—Abbott and MSD Pharmaceuticals—have announced a strategic collaboration to distribute the anti-diabetic medicine sitagliptin and its combinations in India. MSD's sitagliptin and its combinations are marketed in India under the brand names Januvia, Janumet, and Janumet XR. The two American pharmaceutical giants will join hands to leverage Abbott's extensive Indian footprint to distribute this widely used diabetes medication. Sitagliptin, a DPP4 inhibitor used to treat Type 2 diabetes, was launched by MSD in India in 2008. Following the patent expiry in mid-2022, several Indian drugmakers introduced generic versions of the molecule. The sitagliptin market in India is estimated to be worth ₹950–1,000 crore, forming a significant share of the country's ₹20,700 crore diabetes market. MSD said in a statement that its sitagliptin brands continue to be among the leaders in the segment, even after the loss of exclusivity. Before patent expiry, MSD had partnered with Sun Pharmaceutical Industries under a licensing agreement to distribute the drug in India. At that time, there were only four to five sitagliptin brands in the market, including Istavel and Istamet marketed by Sun Pharma. However, post-expiry, the market was flooded with over 150 brands from more than 60 pharmaceutical companies. MSD and Abbott's partnership aims to strengthen the reach of the innovator brands in a competitive market. In India, at least 60 per cent of deaths are attributed to non-communicable diseases (NCDs), with diabetes, cardiovascular conditions, and cancer being the leading causes. The country has an estimated 101 million people with diabetes and 136 million people who are pre-diabetic—at heightened risk of developing the disease in the future. 'As the largest diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system,' said Ambati Venu, vice-president, Abbott India. He added, 'We offer a wide range of solutions to help people manage diabetes more effectively—including testing, continuous glucose monitoring, nutrition, and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health.' Rehan A Khan, managing director, MSD India Region, stated, 'Since its introduction in India over 17 years ago, our sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. Our partnership with Abbott establishes a sustainable business model that will enable us to continue serving patients throughout India with these diabetes treatments.'
Hans India
18-06-2025
- Health
- Hans India
Abbott and MSD Announce Strategic Partnership to Distribute Innovative Oral Anti-Diabetic Medicines in India
Abbott and MSD Pharmaceuticals (tradename of Merck & Co., Inc., Rahway, N.J., USA) are announcing a strategic collaboration through a distribution agreement for MSD's oral anti-diabetic medicine, Sitagliptin, its combination, Sitagliptin/Metformin, and the extended-release version in India. Under this agreement, Abbott will distribute this portfolio, leveraging its broad in-country footprint to continue to make these medicines available to people in India. MSD's Sitagliptin, its combination, and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Sitagliptin is a DPP4i or Dipeptidyl Peptidase IV Inhibitor, used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity. In India, at least 60 per cent of deaths are attributed to non-communicable diseases or NCDs. Amongst these, the leading causes are diabetes, cardiovascular conditions and cancer. The country has an estimated 101 million people with diabetes, and 136 million people who are pre-diabetic, and are at a higher risk of developing diabetes in the future. 'As the largest diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system,' said Ambati Venu, Vice President for Abbott in India. He further added, 'We offer a wide range of solutions to help people manage diabetes more effectively, including testing, continuous glucose monitoring, nutrition and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health.' Rehan A. Khan, Managing Director, MSD India Region stated, 'Since its introduction in India over 17 years ago, our sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'
Economic Times
18-06-2025
- Health
- Economic Times
Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in India
IANS Oral anti-diabetic medicines (Representational Image) Abbott and MSD Pharmaceuticals on Wednesday announced a partnership for distribution of oral anti-diabetic medicines in India. Under a distribution agreement, Abbott will distribute the oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version of MSD Pharmaceuticals (MSD) in India, the two companies said in a joint statement. MSD's sitagliptin, its combination and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Abbott will leverage its broad in-country footprint to continue to make these medicines available to people in India, the statement said. MSD India Region Managing Director, Rehan A Khan, said that since its introduction in India over 17 years ago, the sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. "Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments," he added. India has an estimated 101 million people with diabetes, and 136 million people who are pre-diabetic, and are at a higher risk of developing diabetes in the future, the statement said. Being a large diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system, Ambati Venu, vice president for Abbott in India, said. "We offer a wide range of solutions to help people manage diabetes more effectively, including testing, continuous glucose monitoring, nutrition and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health," he added. Sitagliptin is a Dipeptidyl Peptidase IV Inhibitor (DPP4i) used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after the loss of exclusivity, the statement said.
